Home › Biliary Tract Cancer › Florida › Miami
Biliary Tract Cancer clinical trials in Miami, FL
5 studies for Biliary Tract Cancer are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Miami, Miami
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
- Research Site, Miami
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- University of Miami Hospital and Clinics, Miami
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RecruitingPhase 2
- Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami
Biliary Tract Cancer trials in other cities
- Houston, TX19 studies
- Los Angeles, CA12 studies
- New York City, NY11 studies
- Nashville, TN11 studies
- Boston, MA11 studies
- Arlington, VA9 studies
- Baltimore, MD9 studies
- Dallas, TX8 studies
- Baldwin Park, CA7 studies
- San Antonio, TX7 studies
- Columbus, OH6 studies
- Washington, DC6 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer35 studies
- Prostate Cancer30 studies
- Obesity28 studies
- Ovarian Cancer24 studies
- Acute Myeloid Leukemia24 studies
- Overweight23 studies
- Metastatic Cancer22 studies
- Multiple Myeloma22 studies
- Lung Cancer22 studies
- Alzheimer's Disease21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.